McDermott Advises SolMic on Licensing and Research Cooperation with EMBL


McDermott Will & Emery advised SolMic Research GmbH (SolMic) on a licensing and research cooperation with the European Molecular Biology Laboratory (EMBL).

The aim of the cooperation is to decode the effects of selected plant extracts as used in Traditional Chinese Medicine (TCM). The studies will be advised by EMBL Enterprise Management Technology Transfer GmbH (EMBLEM), a wholly-owned subsidiary of EMBL. The technology portfolio developed by SolMic makes it possible to produce extracts with water-soluble and non-soluble ingredients.

SolMic was founded in 2011 and focuses on technologies for innovative pharmaceuticals, nutraceuticals and cosmetics. The company cooperates with pharmaceutical manufacturers, which has already led to the launch of various products for the European and North American markets. SolMic is currently opening up to the Chinese and Asian markets.

EMBL is Europe’s leading life sciences laboratory. Founded in 1974 as an inter-state organization, it is supported by over 20 member states. With more than 1,600 employees from more than 80 countries, EMBL conducts basic research in molecular biology and offers services in the field of life sciences.

EMBLEM, established in 1999, identifies, protects and markets the intellectual property developed by EMBL. EMBLEM currently manages more than 350 patents and patent filings. EMBLEM also promotes the transfer of innovative technologies from basic research to industry through cooperation with industrial partners in the fields of biotechnology, IT and mechanical and electrical engineering.

The McDermott Team advising SolMic Research GMBH on this transaction was led by life science partner Rüdiger Herrmann and counsel Monika Emilia Richter.

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With 20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,100 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts